{
    "symbol": "IRMD",
    "quarter": 1,
    "year": 2022,
    "date": "2022-04-29 16:20:22",
    "content": " As reported in this morning's release, first quarter revenue was $12.3 million, nearly a 34% increase over the first quarter last year. Considering Q1 with an eye on sales levels and deal count, we now expect the full year 2022 revenue of 52.5 million to 53.2 million with GAAP earnings of $0.89 to $0.95, and non-GAAP earnings of $0.96 to $1.3. Additionally, the second quarter of this year, we expect revenue 12.5 million to 12.7 million with GAAP earnings of $0.21 to $0.23 and non-GAAP earnings of $0.23 to $0.25. As reported earlier this morning, first quarter 2022 revenue was $12.3 million, an increase of 33.5% compared to the first quarter of 2021. The average selling price of our MRI compatible IV infusion system during the first quarter 2022 was approximately $33,800 compared to approximately $32,700 for the first quarter of 2021. The average selling price of our MRI compatible patient vital signs monitoring system during the first quarter 2022 was approximately $46,800 compared to approximately $38,300 for the same period in 2021. As a result, income from operations grew 73% to $3.1 million for the 2022 quarter. We recognize a tax expense during the first quarter 2022 of approximately $573,000 resulting in an effective tax rate of 18.7% compared to a tax expense of approximately $384,000 in the 2021 quarter."
}